2026-05-17T00:18:33Zhttps://repisalud.isciii.es/rest/oai/requestoai:repisalud.isciii.es:20.500.12105/204052024-11-28T23:21:47Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16967
Repisalud
author
Cebrian, Arancha
author
Gomez del Pulgar, Teresa
author
Jose Mendez-Vidal, Maria
author
Luisa Gonzalvez, Maria
author
Lainez, Nuria
author
Castellano, Daniel
author
Garcia-Carbonero, Iciar
author
Esteban, Emilio
author
Isabel Saez, Maria
author
Villatoro, Rosa
author
Suarez, Cristina
author
Carrato, Alfredo
author
Munarriz-Ferrandiz, Javier
author
Basterrechea, Laura
author
Garcia-Alonso, Mirta
author
Luis Gonzalez-Larriba, Jose
author
Perez-Valderrama, Begona
author
Cruz-Jurado, Josefina
author
Gonzalez del Alba, Aranzazu
author
Moreno, Fernando
author
Reynes, Gaspar
author
Rodriguez-Remirez, Maria
author
Boni, Valentina
author
Mahillo-Fernandez, Ignacio
author
Martin, Yolanda
author
Viqueira, Andrea
author
Garcia-Foncillas, Jesus
2024-07-11T09:07:32Z
2024-07-11T09:07:32Z
2017-01-24
Cebrian A, Gomez Del Pulgar T, Mendez-Vidal MJ, Luisa Gonzalvez M, Lainez N, Castellano D, et al. Functional PTGS2 polymorphism-based models as novel predictive markers in metastatic renal cell carcinoma patients receiving first-line sunitinib. Sci Rep. 2017 Jan 24;7:41371.
10.1038/srep41371
2045-2322
Scientific Reports
http://hdl.handle.net/20.500.13003/9981
28117391
L624523881
2-s2.0-85010973193
http://hdl.handle.net/20.500.12105/20405
392482800001
Sunitinib is the currently standard treatment for metastatic renal cell carcinoma (mRCC). Multiple candidate predictive biomarkers for sunitinib response have been evaluated but none of them has been implemented in the clinic yet. The aim of this study was to analyze single nucleotide polymorphisms (SNPs) in genes linked to mode of action of sunitinib and immune response as biomarkers for mRCC. This is a multicenter, prospective and observational study involving 20 hospitals. Seventy-five mRCC patients treated with sunitinib as first line were used to assess the impact of 63 SNPs in 31 candidate genes on clinical outcome. rs2243250 (IL4) and rs5275 (PTGS2) were found to be significantly associated with shorter cancer-specific survival (CSS). Moreover, allele C (rs5275) was associated with higher PTGS2 expression level confirming its functional role. Combination of rs5275 and rs7651265 or rs2243250 for progression free survival (PFS) or CSS, respectively, was a more valuable predictive biomarker remaining significant after correction for multiple testing. It is the first time that association of rs5275 with survival in mRCC patients is described. Two-SNP models containing this functional variant may serve as more predictive biomarkers for sunitinib and could suppose a clinically relevant tool to improve the mRCC patient management.
eng
Functional PTGS2 polymorphism-based models as novel predictive markers in metastatic renal cell carcinoma patients receiving first-line sunitinib
research article